UnitedHealth Crushes Q2, Medical Cost Ratio Hits Two-Year Low

UnitedHealth Group (UNH) turned in a quarter that beat expectations across the board: adjusted EPS of $6.38, up 56.4% from a year ago and roughly 30% above the analyst consensus, while the adjusted medical cost ratio dropped to 86.7% — its lowest level in eight quarters. Management also raised full-year adjusted EPS guidance to $19.50-$20.00, the second consecutive quarterly increase. The stock initially popped on the news before giving back some of those gains. As of the 2026-08-04 close, UNH sat at $407.55, down 1.88% (-$7.81) from the prior close of $415.36. The session opened at $415.555, with a high of $416 and a low of $406.67. With U.S. markets closed for the holiday, the quote is parked at the last trading day's close, with no pre-market or intraday movement.^[TradingKey]

Broad Beat Eases Medical Cost Pressure

UnitedHealth's Q2 adjusted EPS came in at $6.38, well ahead of the $4.94 consensus and a 56.4% jump from the $4.08 reported a year earlier. Revenue for the quarter was $112B, up 0.4% YoY and 1.7% above expectations.^[MarketBeat]

The bigger story for the market was the improvement in the medical cost ratio — the share of premium revenue paid out in medical claims, and the single most important profitability metric for health insurers. It fell to 86.7% from 89.4% a year ago, coming in below the 88.5% analysts had penciled in and marking an eight-quarter low. Total medical costs dropped to $75.4B from $78.6B in the year-ago period.^{[TradingView]}

As TIKR's analysis notes, rising medical costs have been the biggest challenge facing managed-care companies over the past two years. The post-pandemic release of pent-up patient demand — especially higher utilization among Medicare Advantage members — combined with hefty spending on GLP-1 weight-loss drugs to squeeze margins across the industry. UnitedHealth's latest results suggest those pressures are starting to ease.^[TIKR]

Mixed Segments, Optum a Steady Contributor

By segment, insurance arm UnitedHealthcare generated $86B in revenue and $3.9B in operating profit, while health-services business Optum brought in $65.7B in revenue and $4B in operating profit. Total company operating profit rose to $8B from $5.2B a year earlier.^[MarketBeat]

TIKR's analysis shows Optum's operating profit grew 29% YoY to nearly $4B, with operating cash flow of $11.1B. The company's diversified structure once again proved its worth — with the insurance side under pressure, Optum provided a stable profit base through its pharmacy and care-delivery businesses.^[TIKR]

But the challenges haven't fully disappeared. TIKR notes that Medicare Advantage membership has fallen by roughly 965,000 since late 2025, as UnitedHealth exited unprofitable markets. Medicaid margins remain under pressure as reimbursement rates lag medical cost trends. And the Department of Justice's civil and criminal investigations into Medicare Advantage billing practices are still ongoing, leaving the timeline and outcome of that legal overhang uncertain.^[TIKR]

Guidance Raised Again, Analysts Follow Suit

Management lifted its FY2026 adjusted EPS guidance to $19.50-$20.00 in the report. That marks another increase following the Q1 hike, and as MarketBeat notes, it "builds on the previous increase following the first quarter."^[MarketBeat]

Analyst estimates are moving higher in tandem. Per Zacks, the consensus EPS estimate for 2026 now stands at $19.48, implying 19.1% YoY growth; over the past month, that figure has been revised up 11 times with zero downward revisions. The revenue consensus is $446.42B, down 0.3% from a year ago. For 2027, EPS is expected at $22.17, up 13.8% YoY, with 10 upward revisions and none down over the past month. UnitedHealth has beaten earnings estimates in each of the last four quarters, with an average earnings surprise of 12.1%.^{[TradingView]}

MarketBeat notes that UnitedHealth provides commercial, Medicare, and Medicaid coverage to more than 48.5 million people, while its Optum segment supports over 120 million consumers through healthcare services, pharmacy, and technology operations. The company remains one of the most important players in U.S. healthcare.^[MarketBeat]

Stock Outperforms, Valuation Above Historical Median

On price performance, UnitedHealth is up 29.9% year-to-date, outpacing the healthcare sector's 25.8% gain and the S&P 500's 7.8% rise. Among peers, Molina Healthcare (MOH) is up 15.5% YTD, while Centene Corporation (CNC) has gained 55.3%.^{[TradingView]}

TradingKey data rates UnitedHealth's valuation as "fair," ranking it 57th among 74 companies in the healthcare providers & services industry. Over the past month, multiple analysts have issued "Buy" ratings, with a high price target of $473.18. Institutional ownership is very high.^[TradingKey]

The rally, however, has pushed the valuation higher. Zacks notes that UnitedHealth trades at 20.39x forward earnings, above its five-year median of 19.20x and well above the industry average. TIKR data shows a 52-week range of $234.60-$461.62, with the stock at $420.57 (note: TIKR data as of July 30), a Street target of roughly $475, and an NTM P/E of about 20x.^{[TradingView][TIKR]}

MarketBeat's MarketRank™ analysis gives UnitedHealth a "Moderate Buy" rating, with an overall ranking in the 97th percentile, 9.8% upside/downside, a "healthy" short interest level, and "strong" dividend strength.^[MarketBeat]

This content is for informational purposes only and does not constitute investment advice, trading advice, or any guarantee of returns.